Catalent
Q3 2022 Earnings Call
May 03, 2022, 8:15 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Hello, and welcome to the Catalent, Inc. third-quarter fiscal year 2022 earnings conference call. My name is Katie, and I'll be coordinating your call today. [Operator instructions] I'll now hand over to your host, Paul Surdez, vice president, investor relations, to begin.
Paul, please go ahead.
Paul Surdez -- Vice President, Investor Relations
Good morning, everyone, and thank you for joining us today to review Catalent's third-quarter fiscal 2020 financial results. Joining me on the call today are John Chiminski, chair and chief executive officer; Alessandro Maselli, president and chief operating officer; and Tom Castellano, senior vice president and chief financial officer. Please see our agenda for today's call on Slide 2 of our supplemental presentation, which is available on our Investor Relations website at investor.catalent.com. During our call today, management will make forward-looking statements and refer to non-GAAP financial measures.
It is possible that actual results could differ from management's expectations. We refer you to Slide 3 for more detail on forward-looking statements. Slides 4 and 5 discuss Catalent's use of non-GAAP financial measures and our just issued earnings release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Catalent Form 10-Q that will be filed with the SEC today for additional information on the risks and uncertainties that may bear on our operating results, performance, and financial condition, including those related to the COVID-19 pandemic.
Now I'd like to turn the call over to John Chiminski, whose opening remarks will begin on Slide 6 of the presentation.
John Chiminski -- Chairman and Chief Executive Officer
Thanks, Paul, and welcome, everyone, to the call. I'm pleased to report that the positive momentum we built in the first half of our fiscal year continued in the third quarter. Our financial results were driven by strong continued growth in our biologics segment with additional support from our other service offerings, including our consumer-preferred gummy dosage forms for nutritional supplements, which act as an additional growth engine for the company. Our strong performance in the third quarter, coupled with continued momentum, has enabled us to increase our fiscal 2022 guidance for the third time this fiscal year, which Tom will review later in the call.